Assessment of cardiac biomarkers (Troponin, B-type natriuretic peptide, and D-Dimer) in patients with non-valvular atrial fibrillation and stroke
Assessment of cardiac biomarkersAbstract
Objectives: Atrial fibrillation (AF) is the most common arrhythmia treated in clinical practice, and the association of this arrhythmia with stroke has long been recognized. The combination of associated factors to identify stroke risk is still unclear; therefore, we aimed to determine the association between additional risk factors for non-valvular AF (NVAF) and first onset stroke patients and investigate the predictive ability of
additional risks factors such as cardiac biomarkers and AF status for odds of incident stroke.
Materials and Methods: We included 455 patients suffered from NVAF divided into two distinct groups (case–control observational study). Those two groups were based on whether the patients were having a first onset stroke (stroke group) or not having a stroke (non-stroke group). We made the baseline characteristic of our sample group from the substantial evidence of risk factors, lifestyle, and type of AF; to controversial risk described in the new international guideline of AF.
Results: Statistically revealed that heart failure, coronary disease, cigarette smoking, type of AF, warfarin treatment, high sensitive troponin, and B-type natriuretic peptide (BNP) are associated with stroke in NVAF patients (P < 0.05). Otherwise, age, sex, hypertension, kidney disease, diabetes, thyroid disease, alcohol intake, season, aspirin, and D-dimer medication were not associated with stroke (P > 0.05). Multivariate analysis of age, smokers, coronary heart disease, heart failure, high sensitive troponin level, BNP, permanent AF, and warfarin was associated (P < 0.05). The combination of biomarkers with the clinical features can be useful (CHA2DS2-VASc/BS) for the prediction of stroke than CHA2DS2-VASc alone (P < 0.05).
Conclusion: Impact of all associated factors and biological markers as additional risk factors may carry a synergy in this life-threatening event. Additionally, may hold a clinical role which may help to redefine and predict stroke event better than the current CHA2DS2-VASc.
Keywords:
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).